Rimegepant

• Prestige 2 Pending
  2025-521475-31-00 Phase III/IV 1 country Konvent Der Barmherzigen Brueder
• Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patient… Recruiting
  2024-519770-38-00 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
• C4951063: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Recruiting
  2024-517121-10-00 Phase III 6 countries Pfizer Inc.
• A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch… Recruiting
  2024-512382-13-00 Phase III 4 countries Pfizer Inc.
• Open- label study in children and adolescents with migraine: Acute Treatment Recruiting
  2024-512744-32-00 Phase III 2 countries Pfizer Inc.
• A Study to Learn About the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Children and Adolescents. Recruiting
  2024-512743-23-00 Phase III 3 countries Pfizer Inc.
• The rimegePant in RElation to obeSiTy in mIGrainE study Ended
  2024-513359-34-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 Phase IV 10 countries Pfizer Inc.
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan… Ended
  2024-513270-21-00 Phase IV 9 countries Pfizer Inc.
• Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM) Ended
  2024-517128-21-02 Phase IV 1 country Rigshospitalet

Showing 1–10 of 10 trials